McGill University Health Centre (Glen Site)
Montreal, Quebec, H4A 3J1, Canada
NCT Number: NCT06987084
The aim of this randomized placebo-controlled double-blind crossover clinical trial is to test the ability of a traditional tea made from the leaf of the Bryophyllum pinnatum (B. pinnatum) plant in decreasing urinary calcium content in patients with recurrent calcium-based kidney stones.
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Early Phase 1
Montreal, Quebec, H4A 3J1, Canada
Background and Rationale:
Kidney stones are hard deposits that consist of calcium complexed with phosphate or oxalate, thus, high urinary calcium content is a major risk factor. The precipitation of calcium can arise from various mechanisms including the aggregation of urinary calcium crystals from impaired transport along the nephron, reduced urinary inhibitors (e.g. citrate), and increased oxidative stress and inflammation. Large stones can block the drainage system of the kidney, causing acute severe pain and inflammation. Recurrent kidney stones can lead to sustained inflammation resulting in a progressive loss of renal function. As the global incidence and economic burden continues to rise there is a undisputed medical need to find preventative measures.
Thiazide diuretics have been fundamental in pharmacological recurrence prevention for the past 60 years. The recent NOSTONE trial (NCT03057431) revealed that the most widely prescribed and best studied thiazide, hydrochlorothiazide, did not reduce the incidence of stone recurrence. There remain significant barriers to kidney stone treatment including high treatment costs, side effects, and the difficulty in achieving long-term dietary and lifestyle changes. Therefore, many patients risk recurrent episodes. New innovative approaches are needed to prevent kidney stone formation.
The leaves of Bryophyllum pinnatum are used to treat a variety of ailments, including the prevention and treatment of kidney stones in various formulations. In a rat kidney stone model, aqueous, alcoholic, and non-alcoholic extracts of B. pinnatum leaves prevented the formation and reduced the size of kidney stones. In an uncontrolled trial, patients with renal stones treated with B. pinnatum juice either passed their stones or showed a reduction in the size of their stones. Despite its established use in other countries, B. pinnatum tea has not undergone rigorous scientific or clinical evaluation. Our lab characterized and standardized the formulation of the tea which revealed anti-urolithiatic activity along with antioxidant and anti-inflammatory properties. A combination of these effects may be what is beneficial in the prevention of recurrent kidney stones.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
24 g of B. pinnatum leaves boiled in 250 mL of water for 61 minutes sweetened with 1/2 teaspoon of sugar
250 mL of water boiled with 3 g of wheat-bran for 5 minutes sweetened with 1/2 teaspoon of sugar
Time frame: 24 hours after ingestion (day 2 and day 11)
After ingestion of the placebo and treatment, participants will begin a 24 hour urine collection. Urinary calcium levels will be reported as mmol/day.
Time frame: 24 hours after ingestion (day 2 and day 11)
Partipants will be asked if they experience any adverse effects immediately after and 24 hours after ingestion.
Time frame: 24 hours after ingestion (day 2 and day 11)
After ingestion of the placebo and treatment, participants will begin a 24 hour urine collection. Urinary citrate levels will be reported as mmol/day.
Indra Gupta
Other
A Novel Treatment for Recurrent Kidney Stones
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05081960
Calcium Oxalate Kidney Stones, Calcium Oxalate Urolithiasis
London, Ontario, Canada
View Trial DetailsNCT07159503
Calculi, Female Urogenital Diseases
Hangzhou, Zhejiang, China
View Trial DetailsNCT06938113
Calculi, Female Urogenital Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT05269108
Calculi, Female Urogenital Diseases
Cairo, Egypt
View Trial Details